Published April 1, 2026
| Version v1
Journal article
Open
Guillain-Barré Syndrome as a Neurological Disorder and Its Association with Post COVID-19 Vaccination: A Review
Authors/Creators
- 1. 1University Institute of Pharmaceutical Education and Research (UIPER), University of Kota, Rajasthan 2Assistant Professor, University Institute of Pharmaceutical Education and Research (UIPER), University of Kota, Rajasthan
Contributors
- 1. 1University Institute of Pharmaceutical Education and Research (UIPER), University of Kota, Rajasthan 2Assistant Professor, University Institute of Pharmaceutical Education and Research (UIPER), University of Kota, Rajasthan
Description
Abstract
Guillain-Barré syndrome (GBS) is a rare autoimmune neurological disorder affecting the
peripheral nervous system. It is commonly triggered by infections and has also been reported
rarely after vaccination. During the COVID-19 pandemic, cases of GBS following COVID-19
vaccination were reported, raising safety concerns. This review summarizes recent literature
(2016–2025) on the pathophysiology, clinical features, diagnosis, and management of GBS,
with special importance on post-COVID-19 vaccination cases. Evidence suggests a temporal
association, particularly with adenovirus-based vaccines; however, the overall incidence
remains very low. Early diagnosis and rapid treatment result in favourable outcomes. The
benefits of COVID-19 vaccination overshadow the rare risk of neurological complications.
Keywords
Guillain-Barré syndrome, COVID-19 vaccine, neurological disorder, autoimmune disease.
Files
30-34-Guillain-Neha Sharma-488641062.pdf
Files
(554.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:ed6993f2f14585fb1f7bec5c353b673a
|
554.2 kB | Preview Download |
Additional details
References
- 1. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. 2. Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022;145(1):5-9. 3. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. GuillainBarré syndrome spectrum associated with COVID-19: an up-to-date systematic review. Neurol Sci. 2021;42(11):4397-4407. 4. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain Barré syndrome. Lancet. 2021;397(10280):1214 1228. 5. Patone M, Handunnetthi L, Saatci D, et al. Guillain Barré syndrome following COVID-19 vaccination. Nat Med. 2021;27(12):2145-2153. 6. Keh RYS, Scanlon S, Datta-Nemdharry P, et al. COVID 19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain. 2022;145(2):739-748. 7. Maramattom BV, Krishnan P, Paul R, et al. Guillain Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Neurol India. 2021;69(5):13021304. 8. Luijten LWG, van Kammen MS, van Oijen MGH, et al. Guillain-Barré syndrome after COVID-19 vaccination: a systematic review. J Neurol. 2023;270(5):2581 2594. 9. Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682-693. 10. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. 11. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions for immunization safety data. Vaccine. 2019;37(42):6161-6173. 12. Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination. JAMA Netw Open. 2022;5(4): e228879. 13. Li X, Ostropolets A, Makadia R, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination. Clin Infect Dis. 2022;75(7): e1030e1036. 14. Woo EJ, Mba-Jonas A, Dimova RB, et al. Guillain Barré syndrome after Ad26.COV2.S vaccination. JAMA. 2021;326(16):1606-1613. 15. Shao SC, Wang CH, Chang KC, et al. Guillain-Barré syndrome associated with COVID-19 vaccination. Front Immunol. 2021; 12:739215. 16. Kim JE, Min YG, Shin JY, et al. Guillain-Barré syndrome and COVID-19 vaccination: a nationwide cohort study. Eur J Neurol. 2023;30(4):11251133. 17. Fragiel M, Miró Ò, Llorens P, et al. Guillain-Barré syndrome in COVID-19 patients. Clin Microbiol Infect. 2021;27(10):1440-1446. 18. Toscano G, Palmerini F, Ravaglia S, et al. Guillain Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-2576. 19. Dalakas MC. Guillain-Barré syndrome: COVID-19 triggered autoimmune neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e781. 20. Lunn MP, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and Guillain-Barré syndrome. Brain. 2021;144(2):357-360. 21. Allen CM, Ramsamy S, Tarr AW, et al. Guillain-Barré syndrome variant after SARS-CoV-2 vaccination. Ann Neurol. 2021;90(2):315-318. 22. Hippisley-Cox J, Patone M, Mei XW, et al. Neurological complications after COVID-19 vaccination. BMJ. 2021;374: n1786. 23. Andrews N, Stowe J, Ramsay M, et al. Risk of Guillain Barré syndrome after COVID-19 vaccination. Lancet Infect Dis. 2022;22(5):623-631. 24. Waheed S, Bayas A, Hindi F, et al. Guillain-Barré syndrome after Pfizer vaccination. Cureus. 2021;13(2): e13426. 25. Razok A, Shams A, Almeer A, et al. post-COVID-19 vaccine GuillainBarré syndrome. IDCases. 2021;24: e01187. 26. van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis and treatment. Nat Rev Neurol. 2014;10(8):469-482. 27. Nagy A, Alhatlani B. Molecular mimicry in autoimmune disease. Int J Mol Sci. 2020;21(21):8477. 28. Lucchese G, Flöel A. Molecular mimicry between SARS-CoV-2 and human proteins. Autoimmun Rev. 2020;19(8):102548. 29. Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Autoimmune neurological diseases following vaccination. Front Neurol. 2022; 13:832558. 30. Finsterer J. Guillain-Barré syndrome after SARS-CoV 2 vaccination: a systematic review. J Neurol Sci. 2022; 440:120340. 31. Shasha D, Bareket R, Sikron FH, et al. Real-world safety of BNT162b2 vaccine. Clin Microbiol Infect. 2022;28(10): 1533.e1-1533.e6.